On July 28, 2005, Taveras, Arthur G.; Zheng, Junying; Biju, Purakkattle J.; Yu, Younong; Chao, Jianhua; Fine, Jay; Lundell, Daniel; Priestley, Tony; Reggiani, Angelo; Merritt, J. Robert; Baldwin, John J.; Lai, Gaifa; Wu, Minglang published a patent.Electric Literature of 74904-29-3 The title of the patent was Preparation of isothiazole dioxides as CXC- and CC-chemokine receptor ligands. And the patent contained the following:
Disclosed are novel compounds I [D, E = N, CR50; provided that D and E are not the same (one is N and the other is CR50); R50 = H, CF3, CN, etc.; A = (hetero)aryl, (hetero)arylalkyl; B = (hetero)aryl] and the pharmaceutically acceptable salts and solvates thereof. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenesis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound I. Although the methods of preparation are not claimed, hundreds of example preparations and/or characterization data are included. For example, II was prepared in 68% yield from the isothiazoledioxide III and the amine IV.pTSA (preparation of reactants given). Antagonist activities of some examples of I towards CXCR1, CXCR2 and CCR7 are given. The experimental process involved the reaction of 8-Methoxy-3,4-dihydroisoquinolin-1(2H)-one(cas: 74904-29-3).Electric Literature of 74904-29-3
The Article related to isothiazole dioxide preparation chemokine receptor antagonist cxcr1 cxcr2 ccr7 and other aspects.Electric Literature of 74904-29-3
Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem